Prosecution Insights
Last updated: October 22, 2026
Application No. 18/730,020

INACTIVATING AGENT FOR ENVELOPED VIRUSES

Final Rejection §102§103
Filed
Jul 18, 2024
Priority
Jan 28, 2022 — JP 2022-011422 +1 more
Examiner
OGDEN JR, NECHOLUS
Art Unit
1761
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Kao Corporation
OA Round
2 (Final)
70%
Grant Probability
Favorable
3-4
OA Rounds
5m
Est. Remaining
93%
With Interview

Examiner Intelligence

Grants 70% — above average
70%
Career Allowance Rate
734 granted / 1053 resolved
+4.7% vs TC avg
Strong +24% interview lift
Without
With
+23.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
45 currently pending
Career history
1101
Total Applications
across all art units

Statute-Specific Performance

§101
1.5%
-38.5% vs TC avg
§103
47.6%
+7.6% vs TC avg
§102
19.6%
-20.4% vs TC avg
§112
14.7%
-25.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1053 resolved cases

Office Action

§102 §103
Response to Amendment Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-15 is/are rejected under 35 U.S.C. 102(a1) as being anticipated by WO (2021/126956) is withdrawn. Claim(s) 1-21 is/are rejected under 35 U.S.C. 103 as being unpatentable over WO (2021/126956) WO ‘956 discloses a virucidal composition comprising 0.1-50 wt% of a C₈-C₂₂ alpha olefin sulfonate anionic surfactant; additional anionic surfactants such as alkyl sulfosuccinate and particular dioctyl sulfosuccinate; and possibly water (p. 5, I. 3-7). A method of using said composition on a hard surface in need of treatment, in particular contaminated with a non-enveloped virus, for less than 60 min (Claims 13, 17, and 22) is employed for the testing, hard water containing magnesium and calcium (Examples, p. 38, I. 10-13). WO ‘956 also states that a virucidal product that is able to inactivate a non-enveloped virus is also able to inactivate any enveloped virus (p. 1, I. 23-27). The CMC and Kraft point levels are silent with respect to the compositions of WO ‘956 but would have been obvious to the compositions given the single surfactant compositions of sulfosuccinate esters or alpha olefin sulfonates are suggested within their requisite carbon chain lengths and/or branching or non-branching format. Therefore, in the absence of a showing to the contrary, commensurate in scope with the claims, the composition(s) characteristics of a single compound would be the same or similar since they are the same or similar compound/components utilized for the same or similar purpose. Therefore, if the prior art teaches the identical chemical structure, the properties applicant discloses and/or claims are necessarily present (see In re Spada, 911 F.2d 705, 15 USPQ2d 1655, (Fed. Cir. 1990); see also In re Best, 562 F.2d 1252, 195 USPQ 430, (CCPA 1977). "Where the claimed and prior art products are identical or substantially identical in structure or composition, or are produced by identical or substantially identical processes, a prima facie case of either anticipation or obviousness has been established."; MPEP 2112.01 )). [W]hen a patent 'simply arranges old elements with each performing the same function it had known to perform' and yields no more than one would expect from such an arrangement, the combination is obvious. [KSR Int'l Co. v.Teleflex Inc., 550 U.S. at 418 (quoting Sakraida v. Ag Pro, Inc., 425 U.S. 273,282 (1976).] Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to NECHOLUS OGDEN JR whose telephone number is (571)272-1322. The examiner can normally be reached 8-4:30 EST M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Angela Brown-Pettigrew can be reached at 571-272-1498. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /NECHOLUS OGDEN JR/ Primary Examiner, Art Unit 1761
Read full office action

Prosecution Timeline

Jul 18, 2024
Application Filed
May 19, 2026
Non-Final Rejection mailed — §102, §103
Jul 24, 2026
Response Filed
Oct 08, 2026
Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12758474
HYDRO-ALCOHOLIC COMPOSITION FOR HAND DISINFECTION
3y 9m to grant Granted Oct 13, 2026
Patent 12760249
CLEANSING COMPOSITIONS COMPRISING A FATTY ACID AND SOAP MIXTURE AND METHOD FOR MAKING A CLEANSING BAR COMPRISING SAID MIXTURE
3y 5m to grant Granted Oct 13, 2026
Patent 12760243
BIOMASS DERIVED SURFACE-ACTIVE COMPOSITIONS AND PRODUCTS
2y 3m to grant Granted Oct 13, 2026
Patent 12753376
CLEANSING COMPOSITION
2y 6m to grant Granted Oct 06, 2026
Patent 12753366
CLEANING SOLUTION, METHOD FOR CLEANING SUBSTRATE, AND METHOD FOR MANUFACTURING SEMICONDUCTOR
2y 4m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
70%
Grant Probability
93%
With Interview (+23.7%)
2y 8m (~5m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1053 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month